The transaction was approved by both companies' boards and includes a significant premium over recent stock prices for ...

Novartis AG (NYSE:NVS) is one of the 11 best European stocks to invest in. On June 23, the company confirmed it had completed ...

Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common stock, par value $0.001 ...

Novartis today announced that its previously announced tender offer (the “Offer”) by Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), ...

Basel: Novartis has announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. With the ...

Novartis has announced the expiration of its tender offer to acquire Regulus Therapeutics Inc., marking a significant step ...

Novartis AG (NYSE:NVS) is one of the 11 best European stocks to invest in. On June 23, the company confirmed it had completed the acquisition of Regulus Therapeutics.

Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. ("Regulus"). With ...

Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common ...

Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. ("Regulus").

In other recent news, Regulus Therapeutics has entered into an acquisition agreement with Novartis, with the transaction valued at approximately $1.7 billion.